which interacts with another complement receptor, CR3, found on phagocytic cells (24, 25) (Fig. 1) . Further cleavage of iC3b by factor I yields C3c (140 kD) which is released into the fluid phase, and C3dg (41kD) which remains covalently attached to the activator (26) (27) (28) . Additional proteolytic cleavage of C3dg to Cad (35 kD) can be mediated by certain proteases (28) . Activator-bound C3dg or Cad interact with other receptors termed CR2, found on B lymphocytes (15, 29) and CR4, present on phagocytic cells and platelets (30, 31) . Activator-bound C4 is cleaved by factor I successively into iC4b and C4c and C4d (32, 33) . These fragments have not been reported to interact with CR3, CR2, or CR4 .
Factor I requires the participation of cofactor proteins to cleave C3b, iC3b, C4b, and iC4b. The serum proteins factor H (34) and C4 binding protein (C4bp)' (35) , and the cell membrane proteins CR1 (26, 27, 36) , CR2 (37) , and membrane cofactor protein (MCP) (38) all act as cofactors for one or more I-mediated cleavage reactions . Many of the proteins with cofactor activity also regulate the activation and processing of C3 by accelerating decay-dissociation of the C3 activating enzymes of the alternative and classical pathways (39) (40) (41) (42) ) . An additional cell membrane protein, decay-accelerating factor (DAF), lacks cofactor activity but regulates C3 activating enzymes of both pathways (43, 44) .
Certain of these regulatory activities are possessed by glycoprotein C of two herpesviruses, HSV1 (45) (46) (47) and HSV2 (48) . In the course of examining the mechanism of complement activation by EBV, we obtained evidence that EBV acted as a cofactor for factor I-mediated cleavage of C3b. The results of these and further studies indicate that EBV possesses factor I cofactor activity for not only the cleavage of C3b, but also iC3b, C4b, and iC4b. EBV also accelerates the decay of the alternative pathway C3 convertase.
Materials and Methods
Viruses . EBV was purified from supernatants of 12-0-tetradecanoylphorbol-13-acetate (TPA)-treated B95-8 and P3HR1 cells by gradient ultracentrifugation as previously described (49) . The final virus preparations had a concentration of N5 x 10" particles/ml as determined by quantitation ofDNA. Human cytomegalovirus (HCMV) was purified as described (50) , and the amount of infectious virus was determined by a standard plaque assay (51) .
Complement Components and Related Reagents.
Marmoset erythrocytes were obtained through the courtesy ofDr. Suzette Tardiff, Marmoset Research Center, Oakridge Associated University, Oakridge, TN.
C3 was purifed by the method of Hammer et al. (52) with immunoadsorption used to remove albumin, C5, IgG, and IgA. C3 and C4 were radioiodinated with 12 '1-sodium iodide and lodobeads (Pierce Chemical Co., Rockford, IL) according to the manufacturer's instructions to a sp act of 2-4 x 105 cpm/gg . Factors B, D, H, I, and C4bp were kindly provided in purified form by Drs . Leslie Leonard and Hans Miiller-Eberhard, Research Institute of Scripps Clinic and Bernhard Nocht Institute, Hamburg, Federal Republic ofGermany, respectively. Properdin was purified from the euglobulin of normal human serum by chromatography on QAE-Sephadex A25 (Pharmacia Fine Chemicals, Uppsala, Sweden) in 0.15 M Tris buffer (pH 9 .1, 4 mS). The breakthrough fractions were pooled, concentrated, and passed over protein A-Sepharose (Pharmacia Fine Chemicals) followed by specific immunoadsorbent columns to remove Clq and IgG. Human C4 was purified as described (52) . Human C2 was purchased from Diamedix Corporation, Miami, FL.
For assays of C3 cofactor activity, EAC142, prepared with human components and oxidized human C2, were incubated for 20 min at 37°C with 125 1-C3 (100 ug/5 x 108 cells), washed and suspended in GVB (0.1% gelatin, veronal-buffered physiological saline, pH 7.4) at 109 cells/ml. These EAC1423b were converted to EAC142iC3b cells by incubating for 30 min at 37°C with 80 gg offactor I and 70 gg of factor H/109 cells. The cells were then washed and resuspended in GVB . For assays of C4 cofactor activity, sensitized sheep E were sequentially incubated with human Cl and 125 1-C4 (150 ug/109 cells), washed, and suspended in GVB at 109 cells/ml. For rosetting assays, EAC142, EAC1423b, and EAC142iC3b were prepared as above with the substitution of unlabeled human purified C3 for the 125 1-C3 . Also, portions ofthe EAC142iC3b cells were converted to EAC1423d by incubation at 109 cells/ml for 30 min at 37°C with trypsinTPCK (Worthington Biochemical Corp., Freehold, NJ) (20 wg/ml) in GVB . After the incubation, the trypsin was neutralized by the addition of excess soybean trypsin inhibitor and the cells were washed extensively.
For assays of decay-accelerating activity, EAC142 were prepared with limiting amounts of nonoxidized C2 calculated to yield -0.5-1 hemolytic sites per cell. EAC3bBb were prepared as follows : Native C3 was incubated with sheep erythrocytes (100 ug C3 for 109 E) and 5 gg trypsinTPCK in a total volume of 100 gl. The buffer used throughout this preparation was GVB . The cells were incubated at 23°C for 5 min and then washed thoroughly. EC3b were incubated in a final volume of 100 pi with 20 gg of factor B, 0.5 gg of factor D, and either 2 mM NiC12 or 7.5 gg of native properdin together with 2 mM MgC12 to stabilize the convertase .
Antibodies. mAbs to a common class I HLA determinant, W6-32 (American Type Culture Collection, Rockville, MD), HLA-DQ and HLA-DR (Becton Dickinson & Co., Sunnyvale, CA), and BI (Coulter Immunology, Hialeah, FL) were obtained commercially. Monoclonal (3D9) and polyclonal anti-CR1 were kind gifts of Drs . Eric Brown (Washington University, St. Louis, MO) and Brian Tack (Research Institute of Scripps Clinic) respectively. Other mAbs to CR1 were purchased from Becton Dickinson & Co. (44D) and Accurate Chemical Co., Hicksville, NY (833M), respectively. mAbs specific for C3b, C3c, and Cad were kindly provided by Dr. Hans Miiller-Eberhard, Bernhard Nocht Institute, Hamburg, Federal Republic of Germany.
SDS-PAGE and Autoradiography. SDS-PAGE analyses were performed under reducing conditions using the Laemitli buffer system on 10% gels or on 5-15% gradient gels (53) . Samples were boiled for 3 min before electrophoresis . Kodak X-Omat RP film was used for autoradiography.
FACSAnalysis. Pellets of 106 Raji, B95-8, P3HR1, and TI human lymphoblastoid cells as well as TPA-induced B95-8 cells were washed and resuspended on ice in 50-ul volumes of the mAbs to be analyzed . Quantities of the monoclonals used were as follows : Anti-HLA-DQ and DR and BI were used undiluted; mAb 3D9 (anti-CR1, prepared from ascites with octanoic acid) was used at 5-20 ug/ml as specified ; mAb W6-32 (anti-MHC class I clone) was used at a 1 :4 dilution; mAb 44D (anti-CR1, Becton Dickinson & Co.) was used undiluted ; mAb 833M (Accurate Chemical Co.) was used at a 1 :10 dilution . All of the monoclonals were centrifuged for 10 min at 10,000 g before use. The mAbs were incubated with the cells for 1 h on ice and subsequently washed with ice cold PBS-BSA . The pellets were then resuspended in 50 wl of 1 :10 diluted FITC-labeled affinity-purified goat anti-mouse IgG (y chain specific; Kirkegaard & Perry Laboratories, Gaithersburg, MD) and incubated for 30 additional minutes on ice . The cells were washed and resuspended in 0.5 ml of PBS-BSA . Fluorescence analyses were performed with a FAGS (model 440 ; Becton Dickinson & Co.) equipped with a 5 W argon laser operating at 488 nm, 0.3 W. Fluorescence parameters were collected after gating for a combination of forward light scatter and orthogonal light scatter (side scatter), used to discriminate viable from nonviable cells . Data were stored in list mode and analyzed using the Becton Dickinson & Co. Consort 30 FACS data analysis software package .
CofactorActivity Assays . The assay for cofactor activity for the factor I-mediated cleavage of C3b and iC3b has been previously described (26) . Briefly, 101 EAC1423b or EAC1423bi prepared with 1251-C3 were incubated for 30 min at 37°C in a total volume of 100 ttl GVB with factors to be tested for cofactor activity. Factors H and I in amounts indicated in the text, 40 pl B95-8 or P3HR1-derived EBV or HCMV and 10' washed human erythrocytes were added to 10' C3-bearing erythrocytes in various combinations . 80 pg of 3D9 mAb to CRl was also included in certain samples, as indicated in the text . The cells were centrifuged for 2 min at 12,000 g and the supernatants were removed and analyzed by SDS-PAGE under reducing conditions followed by autoradiography. In some experiments, the cell pellets were also extracted with SDS and analyzed by SDS-PAGE under reducing conditions . Quantities of factors to be tested for cofactor activity for the factor I-mediated cleavage of C4b were as follows for 10' cells : 20 ng factor I, 20 pg C4bp, and 40 pl EBV, in various combinations .
Decay-accelerating Activity Assays. Both classical and alternative pathway C3 convertase decay rates were measured by mixing sheep E bearing the appropriate enzyme with the desired concentration of either purified virus, control buffer, or known DAR For each time point in the assay, 10' sheep E in 10 gl were combined with 40 pl of the factor under study, on ice, and then warmed to 30°C quickly in a circulating water bath when timing began . When marmoset or human erythrocytes were assessed for decay-accelerating activity, 10 8 primate erythrocytes were included in the 40 pl . 80 pg of mAb to CRl (3D9) was also included, where specified . At timed intervals, samples of 50 pl were removed and residual convertase activity was measured by the addition of 1 ml guinea pig serum diluted 1 :50 in GVB containing 20 mM EDTA . After further incubation for 20 min at 37°C, the percent hemolysis was calculated and expressed as the reciprocal of the negative natural logarithm of the number of hemolytic sites per cell : [-ln(1-y)] .
C3 Binding Assays. Rosetting of lymphoid cells with sheep erythrocytes bearing complement intermediates was measured as follows . 5 x 10 5 TPA-treated virus-expressing B95-8 or P3HR1 cells, CRl-bearing TI human lymphocytes transformed with B95-8 virus and carried as a lymphoblastoid cell line, or human peripheral blood monocytes (freshly isolated by Ficoll-Hypaque gradient followed by elutriation) were incubated with 5 x 10' complement-bearing sheep erythrocytes (EAC142, EAC1423b, EAC142iC3b, or EAC1423d) in a total volume of 100 gl . After mixing, the cells were briefly pelleted (100 g, 3 min) and the cell pellets were incubated without mixing for 1 h at 37°C . The cell pellets were gently resuspended and rosetting was evaluated on a Zeiss phase contrast microscope . Cells with four or more red cells attached to their surface were considered rosette-positive .
The dot blot immunoassay has been previously described (18, 54) . Briefly, 10 pg of native C3, C3b, C3dg, or C4 were immobilized on nitrocellulose paper. After blocking and wash steps, paper strips containing the blots were incubated at 23°C for 60 min with 50 pl of purified B95-8-derived EBV or TRIS/dextran virus gradient buffer as a negative control diluted to 2 .5 ml in wash buffer. The reagents to detect binding were a biotinylated mAb to the membrane gp350 antigen of EBV (designated BOS-1) (18) streptavidin-horseradish peroxidase (HRP) (Amersham Corp., Arlington Heights, IL) and 2,2'-azinolois(3-ethylbenthiazoline sulfonic acid) (ABTS) chromogenic substrate (250 pg/ml ABTS, 0 .03% H202 in citrate buffer, pH 4 .5) . The assay was also performed in the reverse direction, with 2 .5 pl of purified EBV or virus gradient buffer immobilized on nitrocellulose paper followed, after blocking and washing by 10 pg of the complement fragments . The detection system for this assay used rabbit antisera to the complement fragments, biotinylated goat anti-rabbit IgG (Vector Laboratories, Inc ., Burlingame, CA) streptavidin-HRP and ABTS substrate .
The same type of assay was performed using a previously described ELISA (18, 54) with slight modifications . Microtitration plates were coated with either 5 pl of purified B95-8-derived EBV, HCMV, or control buffer diluted to 50 pl with bicarbonate coating buffer. This coating step proceeded for 18 h at 37°C in an uncovered plate, to allow dessication onto the plate . This step has been found to increase the sensitivity of the assay. After blocking and washing, 10 4g/well of complement fragments were incubated in the wells, in duplicate, at 23°C for 1 h . The antibodies used for detection were mAbs to C3b, C3c, and C3d mixed together. The remainder of the assay was carried out as described earlier.
Direct binding assays to assess EBV attachment to complement-coated erythrocytes were also performed . 5 x 10' EACs in 50 pl were incubated in duplicate with 50 pd of purified EBV (B95-8) for 30 min at 37°C with occasional mixing . The cells were washed twice in PBS containing 0 .2% BSA (PBS(BSA) and the cell pellets were then resuspended in purified mAb to EBV gp350 (BOS-1) at a concentration of 10 pg/ml . Incubation proceeded at 37°C for 30 min followed by two washes . The cell pellets were then incubated with 50 PI of biotinylated goat anti-mouse IgG, diluted 1 :1,000 (Kirkegaard & Perry Laboratories, Inc.) for 30 min at 37°C . After washing, the pellets were resuspended in 50 PI of 125 I_streptavidin (Amersham Corp.) diluted 1 :20 in PBStBSA . Incubation proceeded at 37°C for 30 min after which the cells were washed thoroughly, transferred to clean tubes, and counted in a gamma counter (model 5260 ; Packard Instrument Co., Downers Grove, IL).
Results
C3c Is GeneratedDuring the Incubation ofEBVwith Serum. In the course ofour studies ofcomplement activation by EBV (21), we observed that cleavage products not only characteristic of iC3b, as expected, but also of C3c ( Fig. 1) , appeared during the incubation of purified B95-8 strain EBV with immune human serum containing 1251-C3 (Fig. 2 , lane 1). While minor amounts of the 68-kD and 46-kD C3 fragments characteristic of fluid phase cleavage of C3b into iC3b were found, the most striking feature was the presence of a 25-kD C3 fragment . The size and marked radiolabeling of this fragment are consistent with the NH2-terminal a chain fragment of C3c . Also observed were traces of a 43-kD fragment that could represent the other a' chain fragment or C3dg, which has a molecular weight ofapproximately this size and is poorly radiolabeled by the procedure used. In the control ( C3c is generated during the incubation of EBV with serum. EBV (B95-8) was incubated with normal immune human serum (lane 1) or with EDTA-chelated normal immune human serum (lane 2) supplemented with 1251-C3 for 30 min at 37°C followed by SDS-PAGE analysis and autoradiography under reducing conditions . C3 a (110-kD) and p (75-kD) chains are indicated. The migration positions and molecular masses (kD) of the marker proteins are shown on the right; the molecular masses of the observed bands are indicated on the left .
Although human serum contains cofactors for the factor 1-mediated cleavage of C3b to iC3b (factor H and C4bp), it lacks cofactors for the factor 1-mediated cleavage of iC3b into C3c and C3dg. Thus the appearance of a C3 fragment characteristic of C3c after incubation of EBV with serum suggested to us that EBV either possessed the ability to degrade C3b and iC3b, or acted as a cofactor for their breakdown . These aspects were investigated in the following experiments.
EBV Is a Cofactor for the Factor I-mediated Cleavage of C3b. To determine whether purified EBV either possessed the ability to directly cleave C3b or acted as a cofactor for C3b degradation by factor I, EAC142 125 1-C3b were incubated for 30 min at 37'C with buffer or with various combinations of factor I, factor H, purified EBV, or human erythrocytes (as a source of CR1) . After centrifugation, the supernatants were analyzed by SDS-PAGE under reducing conditions followed by autoradiography. As shown in Fig. 3 , supernatants of cells incubated with B95-8-derived EBV together with factor I revealed the presence of the 106-kD a' and 75-kD R chains indicative of the presence of C3b as well as a 68-kD fragment characteristic of the fluid phase cleavage of the a' chain C3b to generate iC3b (lane 5) . Since the EAC1423 were well washed before incubation with buffer or the other reagents, the presence of C3b and iC3b in the supernatant is most likely explained by spontaneous elution of nonspecifically bound C3b from the cells and its degradation in the fluid phase. Others have also observed degradation products characteristic of iC3b in similar mixtures of factor I, cofactors, and immune complex-bound C3b and interpreted these findings as indicating release and degradation of noncovalently bound C3b (26) . The 68-kD fragment was also observed in supernatants of mixtures containing factors I and H (lane 3) and factor I and human E as a source of CRl (lane 4), both of which served as positive controls . The factor 1-human E mixture also generated a 25-kD fragment, which is characteristic of C3c. The 46-kD a' chain fragment of iC3b is poorly labeled by the method used and thus not seen in the autoradio- In addition to analyzing the supernatants for the presence of C3 derivatives, cellbound C3 fragments were also examined in a number of these studies. Mixtures containing EAC3b together with factor I and either human E or EBV showed the presence of a 68-kD band characteristic of iC3b (not shown) . Since a 68-kD band was not found on cells from mixtures containing EAC3b together with either buffer, factor I, human E, or EBV alone, its presence documents the generation of iC3b from noncovalently bound C3b on the cell surface by factor I acting with either human E or EBV as a cofactor. In addition, EAC3b from all of the reaction mixtures showed the presence of variable amounts of multiple high molecular mass bands (>100 kD) reflecting the covalent attachment of the C3 a' chain, or its fragments to multiple erythrocyte membrane constituents . Small amounts of lower molecular weight bands were also found. Identification of specific bands in these gels was not possible due to the complexity of the patterns .
These above data cumulatively indicate that EBV does not directly degrade C3b but rather acts as a cofactor for the factor I-mediated cleavage of fluid phase or cellbound C3b into iC3b. Because of the inability to identify specific cleavage products of C3 on the cell due to covalent and noncovalent a' chain fragment binding to membrane constituents, as well as the inefficient radiolabeling of C3dg and of the COOHterminal fragment of iC3b, we chose to analyze complement fragments in the supernatants in subsequent studies.
EBV Is a Cofactor for the Factor I-mediated Cleavage of iC3b . To determine whether EBV also possessed the ability to either degrade iC3b, or alternatively, acted as a cofactor for iC3b degradation, EAC142 121 I-iC3b were incubated for 30 min at 37°C with buffer or with various combinations of B95-8-derived EBV and factor I. HCMV another human herpesvirus, was used as a control. After centrifugation the supernatants were analyzed by SDS-PAGE followed by autoradiography. As shown in 3 and 4) . Similar results were obtained in four additional studies of this type with three different preparations of 1395-8-derived EBV These studies indicate that EBV is also a cofactor for the factor I-mediated cleavage of iC3b .
EBV Is a Cofactor for the Factor I-mediated Cleavage of C4b and iC4b . Similar studies to those described above were carried out with EACI 125 1-C4b in order to ascertain whether EBV was also a cofactor for the factor I-mediated cleavage of C4b. As shown in Fig. 5 , supernatants of cells incubated with EBV (B95-8) together with factor EBV accelerates the decay of the nickel-stabilized alternative pathway C3 convertase. Sheep E bearing the nickel stabilized alternative pathway C3 convertase, C3b, Bb, were incubated at 30°C with buffer, EBV (1395-8), or factor H. Periodic samples were incubated with EDTA guinea pig serum as a source of C3-C9, after which lysis was assessed and expressed as -ln(1 -y) . EBV does not accelerate the decay of the classical pathway C3 convertase . EAC142 prepared with human components and nonoxidized C2 were incubated with buffer, EBV (1395-8), or C4bp at 30°C. Periodic samples were incubated with EDTA guinea pig serum as a source of C3-C9, after which lysis was assessed and expressed as -ln(1 -y) .
1395-8-derived EBV. Qualitatively identical results were obtained in two studies of this type carried out with P3HR1-derived EBV.
In contrast, the same amount of EBV (1395-8) did not influence the decay rate of the classical pathway C3 convertase, C4b2a, on sheep E as depicted in Fig. 7 . Similar results were obtained in two other studies of this type . However, C4bp reduced the half-life of the classical pathway C3 convertase from 20 to 10 min (Fig .  7) . Thus, EBV accelerated the rate of decay of the alternative, but not classical pathway C3 convertase .
EBV Does Not Readily Bind to Cab. The above approaches indicated that EBV interacted with factor I to facilitate Cab cleavage and also produced alternative pathway decay acceleration, likely also via an effect on C3b. Some, although not all such cofactors and decay accelerators, bind C3b (see Fig. 12 ). Several approaches were used to assess the potential C3b binding ability of EBV First, the possible ability of EAC3b to form rosettes with TPA-treated B95-8 and P3HR1 cells was examined in several experiments. No rosetting of the virus-expressing cells (in 300 lymphoid cells) with EAC3b was obtained although all of the CRl-bearing T1 human lymphoblastoid cells and most of the monocytes tested in the same experiments formed large rosettes (greater than six erythrocytes per leukocyte) with EAC3b. In a second approach, EBV (1395-8) was incubated with C3b (and other C3 fragments) that had been immobilized on nitrocellulose . Subsequent incubation with a biotinylated mAb to EBV followed by streptavidin HRP and substrate failed to provide evidence for EBV binding. This test system readily detected EBV directly bound to the nitrocellulose. The same assay performed with C3 fragments bound to the wells of microtitration plates also failed to provide evidence for binding of EBV to C3b. This test carried out at onethird normal ionic strength also did not provide evidence for EBV binding. These assays were also performed in the reverse direction, i.e ., by incubating C3b and other C3 fragments with B95-8-derived EBV immobilized on either nitrocellulose or plastic microtitration plate. Rabbit antibody to C3 followed by biotinylated goat anti-rabbit Ig, streptavidin HRP, and substrate were added sequentially. These experiments also failed to provide evidence for EBV binding to C3b. Finally, purified EBV (1395-8) was incubated with EAC3b. Possible binding of EBV was assessed by incubation with an mAb to EBV followed by biotinylated goat anti-mouse Ig, and t25I-streptavidin . The cells after washing were examined for bound radioactivity. These studies did not provide evidence for EBV binding to cell bound C3b. We conclude that the interaction of EBV with C3b, although functionally significant, is too weak or transitory to be directly demonstrated . C3/C4 Cofactor and Decay-accelerating Activities Are Not Due to Crl Associated with or Bound to EBV. Several approaches were used to determine whether the observed C3 regulatory activities were due to CRI acquired from the B95-8 or P3HR1 cell lines during cellular disruption or EBV maturation . As described in the previous section, TPA-treated B95-8 cells failed to form rosettes with EAC3b. This very sensitive assay is the standard functional test for CR1.
Since many of the assays were carried out with EBV derived from the B95-8 cell line, which is of marmoset origin, we sought to determine whether marmoset CRl, if it should be present in EBV derived from the cell line, would crossreact functionally with human complement components . We assessed marmoset erythrocytes, as a source of marmoset CRl, for ability to accelerate decay of the C3bBb convertase since this is not only a sensitive test system for CR1, but also, marmoset cell-derived EBV possesses this activity. However, as shown in Table I , marmoset erythrocytes did not accelerate C3bBb decay while the positive control, human E, did so. The latter activity was also inhibited by the 3D9 mAb to CRl, as anticipated . Qualitatively similar results were obtained in two other assays of this type with erythrocytes from two marmosets. Thus marmoset CRI is not reactive with human C3bBb.
We also examined marmoset B95-8 cells, as well as human P3HR1 cells, for the presence of immunochemically reactive CRl by FACS . As shown in Fig. 8 C, the 3D9 mAb to CRI failed to react with marmoset B95-8 cells. Several other monoclonal antisera directed against human B cell antigens were also examined . As shown, To examine the possibility that undetectable traces of immunochemically reactive CRI possibly present on the cells might be incorporated into EBV, we assessed the ability of monoclonal anti-CRI to inhibit the alternative pathway C3 convertaseaccelerating activity of B95-8 EBV. As shown in Fig. 9 , the decay-accelerating activity of B95-8-derived EBV was not altered by 3D9 anti-CRI whereas the same amount o£ anti-CR1 reversed the decay-accelerating activity of CRI on human E.
Because of uncertainties about detection of marmoset CR1, studies were carried out to assess the possible presence of human CRl on human EBV producing cells or EBV derived from the cells . As noted in the previous section, the P3HR1 EBV producing cells also failed to rosette with EAC3b, the standard functional assay for CRI . Human P3HR1 cells were also examined for the presence of CR1 by FAGS. As shown in Fig. 10 , P3HR1 cells failed to react with either 833M or 44D mAbs to CRI (panel E), whereas T1 lymphoblastoid cells reacted with both antibodies (panel F). B95-8 cells, as noted above, did not react with these antibodies (panel D). An identical pattern of reactivity or nonreactivity was observed with 3D9 mAb to CRI (not shown) . Thus human P3HR1 cells also do not bear immunochemically detectable CRI .
Although CRl could not be detected on the virus-producing cells, we examined whether undetectable traces of CR1 might account for the results by examining the possible ability of anti-CR1 to block cofactor activity of EBV derived from the human cell line. The 3D9 monoclonal anti-CRI examined is known to block CRI func- anti-CRI mAbs with B95-8 (D), P3HR1(E) and TI (F) lymphoblastoid cells are shown, tional activities . In these studies EAC142 1251-C3b were incubated with various combinations of factor H, factor I, human E, P3HR1-derived EBV, and monoclonal 3139 anti-CRI . The supernatants were analyzed by SDS-PAGE as described earlier.
As shown in Fig. 11 , supernatants of cells incubated with P3HR1-derived EBV together with factor I showed the presence of the 68-kD fragment characteristic of iC3b (lane 6), as also observed with B95-8 EBV (Fig . 3) . The 68-kD fragment was also observed in mixtures containing factors I and H (lane 3) and factor I and human E (lane 8), but not in the control lanes (lanes 1, 2, 4 , and 5) . Further cleavage was also observed in the samples containing erythrocytes . Of considerable interest, monoclonal anti-CR1 did not block generation of the 68-kD fragment in reaction mixtures containing EAC3b, factor I, and P3HR1-derived EBV (lane 7) although it efficiently blocked generation of iC3b from Cab by factor I acting together with human E (lane 9) . Similar results were obtained in another study with P3HR1-derived EBV. The various studies described above rule out CR1 as responsible for the biological activities observed . Furthermore, the finding that marmoset B95-8 EBV as well as P3HR1 EBV derived from marmoset and human cells, respectively, possess the same complement regulatory functions strongly suggests that EBV is responsible for the functional properties .
Discussion
A number of molecules have been identified that regulate C 3b and C 4b activation and processing either by acting as cofactors for factor I-dependent cleavage or by accelerating the decay of the C3 convertases (Fig . 12) . We have found complement regulatory activities in purified preparations of EBV derived from virus-producing marmoset and human B lymphoblastoid cells. In the presence of factor 1, EBV enhanced the cleavage of bound C3b to iC3b, iC3b to C3c and C3dg, C4b to iC4b, and iC4b to C4c and C4d. No breakdown of C3b, iC3b, or C4b by EBV was seen in the absence of factor I, indicating that the EBV preparations did not contain proteases capable of degrading these proteins . EBV also accelerated the decay of the alternative pathway, but not the classical pathway C3 convertase . This pattern of reactivity differs from that of all other reported serum, cell membrane, and viral cofactors (Fig . 12) . For example, the serum proteins factor H and C4bp both act as cofactors for the cleavage of C3b to iC3b under physiological conditions (27, 28, 35) and as DAFs for the alternative pathway and classical pathway C3 convertases respectively (39, 40) . The membrane glycoprotein CRl is a cofactor for the cleavage of bound C3b and iC3b as well as C4b and iC4b (26, 27, 36) , it also is a decay accelerating factor for both convertases (41, 42) . The membrane protein DAF has no cofactor activity but decay accelerating activity for both convertases (43, 44) . Another cell surface regulatory factor, MCP, enhances the cleavage of C3b to iC3b by factor I but lacks decay-accelerating activity for both convertases (38) . Neither the activity of MCP in the cell membrane, nor its action on cell-bound C3b has as yet been examined . The spectrum of activities of EBV is most similar to that of CR1, but differs in that EBVexpressing cells, in contrast to CRl-bearing cells, do not rosette with C3b-coated erythrocytes . This is the primary functional assay for CRI. A second distinguishing feature is its inability to accelerate the decay of the classical pathway C3 convertase. Nevertheless, multiple other studies were carried out to determine whether the observed activities might represent the actions of CRl acquired from the virus producing cell lines. Among these, we examined whether marmoset erythrocytes, as a source of marmoset CR1, would accelerate the decay ofthe alternative pathway C3 convertase as do human CRI and EBV Marmoset erythrocytes undoubtedly bear CR1 as do other primate erythrocytes (55) , and have been reported to exhibit C3b (CRI)-dependent rosetting in a somewhat unconventional test system (56) . However, erythrocytes from two marmosets lacked the ability to accelerate decay of the alternative pathway C3 convertase, although human E possessed such activity and this activity was inhibited by anti-CR1 . Next we assessed whether an mAb to CRl could reverse the decay-accelerating activity of B95-8 EBV No effect on the decay rate was noted, although the same antibody reversed the decay-accelerating activity of CR1 on human erythrocytes . We also evaluated whether CRI could be detected on TPA-treated marmoset B95-8 cells with three mAbs to CR1 as well as a polyclonal antibody to CRl. No reactivity was observed . Since the B95-8 cell line is of marmoset origin and the antibodies are directed against human proteins, we examined multiple antisera to human cell surface antigens to determine whether crossreactivity of the antisera with marmoset cell surface antigens is commonly observed. Good reactivity with antibody to a common HLA class I determinant, to HLA-DR, and to the human B1 antigen was observed . Although HLA-DQ was not detected on the marmoset cells, this finding must be interpreted with caution since human B cells and lymphoblastoid cells vary considerably in their expression of the two MHC class II determinants, HLA-DQ and HLA-DR.
The strong crossreactivity of antibodies to human MHC class I, HLA-DR, and B1 antigens with the equivalent antigens on the marmoset B95-8 cells coupled with the absence of reactivity with monoclonal and polyclonal antibodies to human CRI suggested that the virus-producing marmoset B95-8 cells lack CRI. The failure of anti-CRI to block the decay-accelerating activity of B95-8-derived EBV also implied that CRl was not responsible for the observed activity. Finally, the studies with marmoset erythrocytes suggested that marmoset CRI, even if present, would be unable to accelerate human C3bBb decay as did EBV. Nevertheless, some uncertainty remained because of the different species involved . To definitively eliminate the possibility that CR1 in the EBV preparations was responsible for the observed activities, we carried out a number of studies with human P3HR1 EBVproducing cells and with EBV purified from the human cells.
First, we evaluated whether P3HR1 cells would rosette with C3b-bearing erythrocytes. No reactivity was observed although known CRI-bearing controls readily rosetted . Second, we assessed the presence of CR1 on the P3HR1 cells with three mAbs to CRI. No reactivity was found although the antibodies reacted with CRI bearing, non-EBVproducing human B lymphoblastoid cells. Third, the factor I cofactor activity of purified EBV from the P3HR1-bearing cells was not blocked by the 3D9 mAb to CR1 although this antibody inhibited human E-mediated, CR1-dependent cofactor activity in the same experiments.
The above studies cumulatively indicate that CRl is not responsible for the factor I cofactor and decay-accelerating activities exhibited by purified EBV preparations . We have not directly examined whether the observed activities are properties of EBV or of a cellular protein other than CRl incorporated into, or attached to EBV. We feel, however, that the regulatory properties are most likely virus related for three reasons. First, the spectrum of activities differs from that of any of the known cellular or serum cofactors (Fig . 12) . Second, EBV derives its envelope from the nuclear membrane, not the plasma membrane ; furthermore, cellular proteins tend to be excluded from viral envelopes. Also, the virus-containing supernatant is subjected to ultrafiltration before initiating purification, and isolation is by banding in a rate zonal density gradient . Finally, and most telling, EBV preparations derived from both marmoset and human cell lines possessed the same decay-accelerating and factor I cofactor activities . It is unlikely that cells from the two species possess a principle that regulates human complement components and that is incorporated into EBV from the two cell lines. It is more probable that the functional regulatory activities are properties of a protein encoded by the viral genome . A final answer, however, must await the isolation and characterization of the factor.
Approximately 2 x 109 EBV particles possessed somewhat less factor I cofactor activity for C3b cleavage than 10' human erythrocytes (Fig . 3) . The human erythrocytes likely possess -1,000 CRl per cell (57) since they were preselected for high activity. The regulatory activity of EBV is clearly less than that of CRl in this test system, although it is within the published range of activity of other regulatory proteins. For example, MCP is more than 50 times as active as factor H in acting as a factor I cofactor for C3b cleavage (38) . Factor H is 2 times more active than CR1 which in turn is 17 times more efficient than C4bp (58) . The efficiency of these factors in this test system thus spans more than a 3-log range. Clearly, such quantitative assessments in nonphysiological, nonoptimized test systems do not reflect biological effectiveness in vivo . This is particularly true of EBV, which is unlikely to have evolved and maintained this trait if it did not provide a protective advantage for the virus.
For the cofactor and decay-accelerating activities of EBV to be biologically meaningful, they would have to act on C3b bound to the same viral particle because multiple EBV particles would not likely be found in close proximity in vivo. Although both CRl (59) and DAF (44) , two of the membrane-associated complement regulatory proteins, possess the abiltiy to act on C3b attached to the same cell (intrinsic activity), the relative intrinsic versus extrinsic activity (for C3b bound to other cells or immune complexes) remains to be determined for MCP and HSV gC as well as for EBV.
Other herpes viruses have also been found to encode various proteins that interact with the humoral immune system . Thus, infection of human cells with other herpes viruses, including HSV1, HSV2, cytomegalovirus, and varicella zoster virus results in the appearance on the cell surface of virally encoded receptors for the Fc portion of human IgG (60) (61) (62) . HSV1 also induces the appearance of a C3b receptor in the plasma membrane of infected cells (46, 63) , and this has been identified as a viral glycoprotein, gC (45, 47) . This viral C3b receptor is reactive with an mAb to human CRl (46) ; it also modulates complement activation as it has decayaccelerating activity for the alternative pathway C3 convertase, and interferes with the interaction of C3b with C5, although it lacks cofactor activity (45) . Recently gC of HSV2 has been reported to possess the ability to bind iC3 (48) . Other human pathogens including bacteria (64, 65) and fungi (66, 67) have been found to possess Fc or C3 binding properties . Although the biological significance of these various activities is far from clear, it is probable that they have evolved to provide survival value for the pathogens.
In this regard, the various EBV complement regulatory activities reported in this paper may enable EBV and EBVinfected cells to evade destruction by humoral immune mechanisms . Since EBV and EBVinfected cells activate complement, the virions as well as the infected cells would become coated with Cab as well as other complement components on contact with plasma . This could facilitate cytolytic destruction of the virus or virus-infected cell by either complement-or lymphocyte-dependent cytolytic mechanisms (68) ; it could also augment opsonization and phagocytic destruction by complement receptor-bearing cells (23) . Furthermore, the ability of the virus to accelerate the decay of the alternative pathway C3 convertase would retard additional activation, while the cofactor activity for both factor I-mediated cleavages of C3 as well as C4 would rapidly convert bound C3b and C4b to bound C3dg and C4d which do not readily interact with phagocytic CRl and CR3 receptors. The ability of EBV to facilitate the degradation of C3b on the viral surface to C3dg may restore infectivity by permitting the virus to again bind to CR2 via C3dg. These various activities could thus all be viewed as promoting viral survival. Since the effects on EBV infectivity can be experimentally determined, further study will indicate whether they do indeed permit EBV to evade destruction by complement-and celldependent host defense mechanisms .
Summary
Serum incubated with purified EBV was found to contain C3 cleavage fragments characteristic of C3c. Since the cofactors necessary for such cleavage of C3b by factor I are not normally present in serum, EBV was tested for factor I cofactor activity. Purified EBV from both human and marmoset EBVproducing cell lines was found to act as a cofactor for the factor I-mediated breakdown C3b to iC3b and iC3b to C3c and C3dg . EBV also acted as a cofactor for the factor I-mediated cleavage of C4b to iC4b and iC4b to C4c and C4d. EBV from both the human and marmoset cell lines accelerated the decay of the alternative pathway C3 convertase . The classical pathway C3 convertase was unaffected . Multiple lines of evidence eliminated the possibility that marmoset or human CRl was responsible for the functional activities of EBV preparations . The spectrum of activities was different from CR1 in that EBV and EBVexpressing cell lines failed to rosette with C3b or particles bearing C3b, the primary functional assay for CR1, and EBV did not accelerate classical pathway C3 convertase decay, another property of CR1. In addition, CRl could not be detected immunologically on marmoset or human EBVexpressing cells and mAbs to CR1 failed to alter EBVproduced decay acceleration and factor I cofactor activities, although the antibodies blocked the same CR1-dependent functional activities . The multiple complement regulatory activities exhibited by purified EBV derived from human and marmoset cells differ from those of any of the known C3 or C4 regulatory proteins . These various activities would be anticipated to provide survival value for the virus by subverting complement-and cell-dependent host defense mechanisms .
